Alzheimer's disease is a common problem in our elderly population. Although research is leading to improvements in our understanding of the underlying biology, we still have little understanding of the environmental risk factors associated with this disorder. Caffeine, an easily modifiable environmental factor, may have a protective effect on the likelihood of developing Alzheimer's disease. This article reviews the association between caffeine from both a biologic and epidemiologic perspective. Further studies are needed to determine whether caffeine consumption could have a major affect on the development of Alzheimer's disease or age-related cognitive decline.
Sloane PD, Zimmerman S., Suchindran C., et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002;23:213-231.
2.
Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord. 2008;23:888-895.
3.
Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson's disease. Arch Neurol. 2007; 64:576-580.
4.
Rudolphi KA, Keil M., Fastbom J., Fredholm BBIschaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci Lett . 1989;103:275-280.
5.
Popoli P., Blum D., Martire A., Ledent C., Ceruti S., Abbracchio MPFunctions, dysfunctions and possible therapeutic relevance of adenosine A2a receptors in Huntington's disease. Prog Neurobiol. 2007;81:331-348.
6.
Bjorklund O. , Kahlstrom J., Salmi P., et al. The effects of methylmercury on motor activity are sex- and age-dependent, and modulated by genetic deletion of adenosine receptors and caffeine administration. Toxicology . 2007;241:119-133.
7.
Ritchie K., Carriere I., De Mendonca A., et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007 ;69: 536-545.
Johnson-Kozlow M., Kritz-Silverstein D., Barrett-Connor E., Morton D.Coffee consumption and cognitive function among older adults. Am J Epidemiol . 2002;156: 842-850.
10.
Maia L., De Mendonca A.Does caffeine intake protect from Alzheimer's disease? Eur J Neurol. 2002;9: 377-382.
11.
van Gelder BM, Buijsse B., Tijhuis M., et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007;61:226-232.
12.
Lindsay J., Laurin D., Verreault R., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol . 2002;156:445-453.
13.
Tyas SL, Manfreda J., Strain LA, Montgomery PRRisk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001 ;30:590-597.
14.
Van Boxtel MPJ , Schmitt JAJ, Bosma H., Jolles J.The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav . 2003;75:921-927.
15.
Fredholm BB , Battig K., Holmen J., Nehlig A., Zvartau EEActions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
16.
Ribeiro JA, Sebastiao AM, De Mendonca A.Adenosine receptors in the nervous system: pathophysiological implications . Prog Neurobiol. 2003;68:377-392.
17.
de Mendonça A., Sebastião AM, Ribeiro JAAdenosine: does it have a neuroprotective role after all? Brain Res Rev. 2000;33:258-274.
18.
Dall'Igna OP , Fett P., Gomes MW, Souza DO, Cunha RA, Lara DRCaffeine and adenosine A 2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol. 2007;203: 241-245.
19.
Dall'Igna OP , Porciuncula LO, Souza DO, Cunha RA, Lara DRNeuroprotection by caffeine and adenosine A2a receptor blockade of beta-amyloid neurotoxicity . Br J Pharmacol. 2003;138:1207-1209.
20.
Prediger RDS , Batista LC, Takahashi RNCaffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats: Involvement of adenosine A1 and A2a receptors. Neurobiol Aging . 2005; 26:957-964.
Svilaas A., Sakhi AK, Andersen LF, et al. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr. 2004; 134:562-567.
23.
Jacobson KA, von Lubitz Dkje, Daly JW, Fredholm BBAdenosine receptor ligands: differences with acute versus chronic treatment . Trends Pharmacol Sci. 1996; 17:108-113.
24.
Meyer PT, Elmenhorst D., Boy C., et al. Effect of aging on cerebral A1 adenosine receptors: A [18F] CPFPX PET study in humans. Neurobiol Aging. 2007 ;28: 1914-1924.
25.
Arendash GW, Schleif WS, Rezai-Zadeh K., et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience. 2006;142:941-952.
26.
Angulo E., Casado V., Mallol J., et al. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer's disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003;13:440-451.
27.
Acquas E., Tanda G., Di Chiara G.Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacol. 2002;27:182-193.
28.
Karadsheh N. , Kussie P., Linthicum DSInhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives. Toxicol Lett. 1991;55: 335-342.
29.
Carter AJ, O'Connor WT, Carter MJ, Ungerstedt U.Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J Pharmacol Exp Ther . 1995;273: 637-642.
30.
Shi D., Nikodijevic O., Jacobson KA, Daly JWChronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol. 1993;13:247-261.
31.
Rees K., Allen D., Lader M.The influences of age and caffeine on psychomotor and cognitive function . Psychopharmacology. 1999;145:181-188.
32.
Riedel WJ, Hogervorst E., Leboux R., Verhey F., van Praag H., Jolles J.Caffeine attenuates scopolamine-induced memory impairment in humans . Psychopharmacology. 1995; 122:158-168.
33.
Hameleers PA , Van Boxtel MP, Hogervorst E., et al. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol . 2000;15:573-581.
